Stryker (NYSE:SYK) Price Target Raised to $454.00

Stryker (NYSE:SYK) had its price objective upped by Needham & Company LLC from $448.00 to $454.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the medical technology company’s stock. Needham & Company LLC’s target price points to a potential upside of 28.11% from the company’s current price.

SYK has been the topic of several other research reports. Wells Fargo & Company lifted their target price on Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. BTIG Research raised their price target on Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a report on Friday. Sanford C. Bernstein lifted their price objective on shares of Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Truist Financial decreased their target price on shares of Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a research report on Thursday, December 18th. Finally, Evercore ISI set a $390.00 target price on shares of Stryker in a research note on Monday, January 5th. Twelve analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $426.39.

Stryker Trading Down 1.0%

Stryker stock opened at $354.39 on Friday. Stryker has a 52-week low of $329.16 and a 52-week high of $404.87. The company has a quick ratio of 1.13, a current ratio of 1.85 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $135.53 billion, a price-to-earnings ratio of 46.57, a PEG ratio of 2.29 and a beta of 0.89. The firm has a 50-day moving average price of $359.38 and a two-hundred day moving average price of $371.95.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating the consensus estimate of $4.40 by $0.07. The company had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. Stryker had a net margin of 12.07% and a return on equity of 24.07%. Stryker’s revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the business earned $4.01 earnings per share. Sell-side analysts expect that Stryker will post 13.47 earnings per share for the current year.

Insider Buying and Selling

In other Stryker news, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the transaction, the chief financial officer owned 6,694 shares in the company, valued at approximately $2,449,200.72. The trade was a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO William E. Berry, Jr. sold 1,953 shares of the company’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the transaction, the chief accounting officer directly owned 2,833 shares in the company, valued at $1,035,433.17. This represents a 40.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 522,118 shares of company stock worth $185,381,932. Corporate insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Stryker

A number of hedge funds and other institutional investors have recently modified their holdings of SYK. Mid American Wealth Advisory Group Inc. acquired a new stake in Stryker during the 2nd quarter worth about $26,000. Clayton Financial Group LLC purchased a new position in shares of Stryker in the third quarter worth approximately $26,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of Stryker during the second quarter valued at approximately $28,000. Sachetta LLC lifted its position in shares of Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after acquiring an additional 27 shares in the last quarter. Finally, Kilter Group LLC purchased a new stake in shares of Stryker in the 2nd quarter valued at approximately $29,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly beat — Stryker posted Q4 adjusted EPS $4.47 (vs. $4.40 consensus) and revenue $7.17B, with organic sales up ~11% and adjusted operating margin expanding 100 bps, signaling continued top‑line momentum and operating leverage. Stryker reports 2025 operating results and 2026 outlook
• Positive Sentiment: Raised outlook/supportive commentary — Management now guides 2026 organic net sales growth of 8.0%–9.5% and adjusted EPS $14.90–$15.10 and indicated modestly favorable pricing and FX, prompting firms to keep/confirm Buy ratings. Reuters notes management raised its profit forecast tied to strong capital and implant demand. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Analyst support — Multiple shops (Needham, Piper Sandler and others) reiterated Buy/Overweight ratings after the results, citing sustained double‑digit growth in key MedSurg/Neuro businesses and improved margins. Stryker: Sustained Double-Digit Growth and Operating Leverage Support Buy Rating
• Neutral Sentiment: FY26 EPS range roughly in line with consensus — the $14.90–$15.10 range centers near Street estimates (consensus ~14.96). That calmingly conservative guidance reduces upside surprise potential and helps explain muted share reaction despite the beat.
• Neutral Sentiment: Earnings call / details available — full Q4 earnings call transcript and company presentation provide more color on product momentum, capital demand and margin drivers for investors reviewing catalysts. Stryker Q4 2025 Earnings Call Transcript
• Negative Sentiment: Tariff/regulatory risks flagged — some analysts and the company note potential 2026 tariff headwinds and geopolitical/regulatory risks that could pressure margins or growth in certain markets if they materialize.
• Negative Sentiment: Large insider selling noted by data providers — recent public filings and data aggregators show substantial insider share sales over the past 6 months, which can amplify sell‑side pressure or signal near‑term positioning changes. QuiverQuant summary & insider activity
• Negative Sentiment: Product/segment items — notable declines or one‑time items (e.g., a material drop in spinal implants year/quarter comparisons and earlier goodwill/impairment charges) remain on the P&L and are potential longer‑term headwinds for parts of Orthopaedics. Stryker reports 2025 operating results and 2026 outlook

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.